Motesanib Diphosphate in Progressive Differentiated Thyroid Cancer von Sherman, Steven I, Wirth, Lori J, Droz, Jean-Pierre, Hofmann, Michael, Bastholt, Lars, Martins, Renato G, Licitra, Lisa, Eschenberg, Michael J, Sun, Yu-Nien, Juan, Todd, Stepan, Daniel E, Schlumberger, Martin J

Volltext

Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer von SCHLUMBERGER, Martin J, ELISEI, Rossella, ESCHENBERG, Michael J, SUN, Yu-Nien, JUAN, Todd, STEPAN, Daniel E, SHERMAN, Steven I, BASTHOLT, Lars, WIRTH, Lori J, MARTINS, Renato G, LOCATI, Laura D, JARZAB, Barbara, PACINI, Furio, DAUMERIE, Chantal, DROZ, Jean-Pierre

Volltext

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer von KARLAN, Beth Y, OZA, Amit M, COVENS, Allan, NAGARKAR, Raj V, DAVY, Margaret, LEATH, Charles A, NGUYEN, Hoa, STEPAN, Daniel E, WEINREICH, David M, TASSOUDJI, Marjan, SUN, Yu-Nien, VERGOTE, Ignace B, RICHARDSON, Gary E, PROVENCHER, Diane M, HANSEN, Vincent L, BUCK, Martin, CHAMBERS, Setsuko K, GHATAGE, Prafull, PIPPITT, Charles H, BROWN, John V

Volltext

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer von Makker, Vicky, Taylor, Matthew H., Aghajanian, Carol, Oaknin, Ana, Mier, James, Cohn, Allen L., Romeo, Margarita, Bratos, Raquel, Brose, Marcia S., DiSimone, Christopher, Messing, Mark, Stepan, Daniel E., Dutcus, Corina E., Wu, Jane, Schmidt, Emmett V., Orlowski, Robert, Sachdev, Pallavi, Shumaker, Robert, Casado Herraez, Antonio

Volltext

Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial von Makker, Vicky, Rasco, Drew, Vogelzang, Nicholas J, Brose, Marcia S, Cohn, Allen L, Mier, James, Di Simone, Christopher, Hyman, David M, Stepan, Daniel E, Dutcus, Corina E, Schmidt, Emmett V, Guo, Matthew, Sachdev, Pallavi, Shumaker, Robert, Aghajanian, Carol, Taylor, Matthew

Volltext

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors von Taylor, Matthew H., Lee, Chung-Han, Makker, Vicky, Rasco, Drew, Dutcus, Corina E., Wu, Jane, Stepan, Daniel E., Shumaker, Robert C., Motzer, Robert J.

Volltext

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors von Benjamin, Robert S., Schöffski, Patrick, Hartmann, Jörg Thomas, Van Oosterom, Allan, Bui, Binh Nguyen, Duyster, Justus, Schuetze, Scott, Blay, Jean-Yves, Reichardt, Peter, Rosen, Lee S., Skubitz, Keith, McCoy, Sheryl, Sun, Yu-Nien, Stepan, Daniel E., Baker, Laurence

Volltext

Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation von van Burik, Jo-Anne H., Ratanatharathorn, Voravit, Stepan, Daniel E., Miller, Carole B., Lipton, Jeffrey H., Vesole, David H., Bunin, Nancy, Wall, Donna A., Hiemenz, John W., Satoi, Yoichi, Lee, Jeanette M., Walsh, Thomas J.

Volltext

Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection von Lu, Jian-Feng, Rasmussen, Erik, Karlan, Beth Y., Vergote, Ignace B., Navale, Lynn, Kuchimanchi, Mita, Melara, Rebeca, Stepan, Daniel E., Weinreich, David M., Sun, Yu-Nien

Volltext

Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Im... von Leis, Jose F, Stepan, Daniel E, Curtin, Peter T, Ford, John M, Peng, Bin, Schubach, Susan, Druker, Brian J, Maziarz, Richard T

Volltext

Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma von Taylor, Matthew H., Vogelzang, Nicholas J., Cohn, Allen Lee, Stepan, Daniel E., Shumaker, Robert Charles, Dutcus, Corina E., Guo, Matthew, Schmidt, Emmett V., Rasco, Drew W.

Volltext

A phase 2 trial of lenvatinib 18 mg versus 14 mg once daily (QD) in combination with everolimus (5 mg QD) in renal cell carcinoma (RCC) after 1 prior VEGF-targeted treatment von Glen, Hilary, Puente, Javier, Heng, Daniel Yick Chin, Rha, Sun Young, Li, Di, Stepan, Daniel E., Dutcus, Corina E., Pal, Sumanta K.

Volltext

Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results von Lee, Chung-Han, Makker, Vicky, Rasco, Drew W., Taylor, Matthew H., Stepan, Daniel E., Shumaker, Robert Charles, Schmidt, Emmett V., Guo, Matthew, Dutcus, Corina E., Motzer, Robert J.

Volltext

A phase Ib/II trial of lenvatinib plus pembrolizumab in non-small cell lung cancer von Brose, Marcia S., Vogelzang, Nicholas J., DiSimone, Christopher, Jain, Sharad K., Richards, Donald A., Encarnacion, Carlos A., Rasco, Drew W., Shumaker, Robert Charles, Dutcus, Corina E., Stepan, Daniel E., Guo, Matthew, Schmidt, Emmett V., Taylor, Matthew H.

Volltext

Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer von Vogelzang, Nicholas J., Encarnacion, Carlos A., Cohn, Allen Lee, DiSimone, Christopher, Rasco, Drew W., Richards, Donald A., Taylor, Matthew H., Dutcus, Corina E., Stepan, Daniel E., Shumaker, Robert Charles, Guo, Matthew, Schmidt, Emmett V., Mier, James Walter

Volltext

A phase Ib/II trial of lenvatinib (LEN) plus pembrolizumab (Pembro) in patients (Pts) with endometrial carcinoma von Makker, Vicky, Rasco, Drew W., Dutcus, Corina E, Stepan, Daniel E., Li, Di, Schmidt, Emmett V., Shumaker, Robert Charles, Taylor, Matthew H.

Volltext

A phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with squamous cell carcinoma of the head and neck von Taylor, Matthew H., Rasco, Drew W., Brose, Marcia S., Vogelzang, Nicholas J., Richey, Stephen Lane, Cohn, Allen Lee, Richards, Donald A., Stepan, Daniel E., Dutcus, Corina E., Guo, Matthew, Shumaker, Robert Charles, Schmidt, Emmett V., Wirth, Lori J.

Volltext

Lenvatinib + pembrolizumab in patients with advanced endometrial cancer: Updated results von Makker, Vicky, Rasco, Drew W., Vogelzang, Nicholas J., Messing, Mark, Brose, Marcia S., Cohn, Allen Lee, Aghajanian, Carol, Stepan, Daniel E., Dutcus, Corina E., Schmidt, Emmett V., Guo, Matthew, Sachdev, Pallavi, Shumaker, Robert Charles, Taylor, Matthew H.

Volltext

Safety and efficacy of lenvatinib by starting dose (8 mg or 12 mg) based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT von Okusaka, Takuji, Ikeda, Kenji, Kudo, Masatoshi, Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Cheng, Ann-Lii, Piscaglia, Fabio, Kobayashi, Masahiro, Sung, Max W., Chen, Minshan, Wyrwicz, Lucjan, Yoon, Jung-Hwan, Ren, Zhenggang, Stepan, Daniel E., Dutcus, Corina E., Tamai, Toshiyuki, Ren, Min, Hayato, Seiichi, Kumada, Hiromitsu

Volltext

Thalidomide as Salvage Therapy for Chronic Graft-Versus-Host Disease von Parker, Pablo M., Chao, Nelson, Nademanee, Auayporn, O'Donnell, Margaret R., Schmidt, Gerhard M., Snyder, David S., Stein, Anthony S., Smith, Eileen P., Molina, Arturo, Stepan, Daniel E., Kashyap, Ashwin, Planas, Ina, Spielberger, Ricardo, Somlo, George, Margolin, Kim, Zwingenberger, K., Wilsman, K., Negrin, Robert S., Long, Gwynn D., Niland, Joyce C., Blume, Karl G., Forman, Stephen J.

Volltext